The continuing challenge of exocrine pancreatic cancer.
Carcinoma of the exocrine pancreas continues to have one of the poorest outlooks of any cancer. Although worthwhile gains in survival may be achieved by early diagnosis and referral to a specialist surgeon, further improvements are unlikely without reliable screening techniques and improved adjuvant therapy.
Worthington
T R
TR
Department of Gastrointestinal Surgery, Imperial College School of Medicine, London, United Kingdom.
Williamson
R C
RC
D000368:Aged; D000369:Aged, 80 and over; D000931:Antidotes / Q000008:administration & dosage; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D002760:Cholangiopancreatography, Endoscopic Retrograde; D048909:Diabetes Complications; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D010180:Pancreatectomy; D010190:Pancreatic Neoplasms / Q000175:diagnosis* / Q000601:surgery / Q000628:therapy*; D016577:Pancreaticoduodenectomy; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013997:Time Factors; D014055:Tomography, Emission-Computed; D014057:Tomography, X-Ray Computed
D000931:Antidotes; D000964:Antimetabolites, Antineoplastic; D002955:Leucovorin; D005472:Fluorouracil